Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRA737 in advanced cancer
NCT02797964Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SRA-737 in solid tumor (advanced stage) and non-Hodgkin lymphoma (NHL), sponsored by GSK. Primary endpoints: Number of Subjects With Adverse Events as Assessed by CTCAE 4.03, Maximum Tolerated Dose of SRA737 and 5 more. Started Jul 2016; status: completed.
02
Drugs
SRA-737
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02797964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797964.